|
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset |
|
|
|
Titel: |
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset |
Auteur: |
Cho, Byoung Chul Hayashi, Hidetoshi Lee, Jong-Seok Lee, Se-Hoon Danchaivijitr, Pongwut Cheng, Ying Liu, Baogang Alip, Adlinda Xiong, Hailin How, Soon Hin Chang, Gee-Chen Yang, James Chih-Hsin Yoshioka, Hiroshige Nahit Şendur, Mehmet Ali Prabhash, Kumar Azuma, Koichi Lee, Yun-Gyoo Lin, Chien-Chung Matsumoto, Shingo Sunpaweravong, Patrapim Xia, Yichuan Martinez, Melissa Bauml, Joshua M. Sethi, Seema Lu, Shun |
Verschenen in: |
Lung cancer |
Paginering: |
Jaargang 204 () nr. C pagina's p. |
Jaar: |
2025 |
Inhoud: |
|
Uitgever: |
The Authors |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|